Johnson & Johnson Expects 2024 Reported Sales Of $88.4B–$88.8B Compared To Prior Guidance Of $88.0B–$88.4B And Consensus Of $88.51B

Benzinga · 10/15 10:25
Note: Adjusted operational EPS figures reflect midpoint of issued guidance
($ in Billions, except EPS) October 2024 July 2024

Adjusted Operational Sales1,2,5

Change vs. Prior Year / Mid-point

 5.7% – 6.2% / 6.0% 5.5% – 6.0% / 5.8%
Operational Sales2,5/ Mid-point $89.4B – $89.8B / $89.6B $89.2B – $89.6B / $89.4B
Change vs. Prior Year / Mid-point 6.3% – 6.8% / 6.6% 6.1% – 6.6% / 6.4%
Estimated Reported Sales3,5/ Mid-point $88.4B – $88.8B / $88.6B $88.0B – $88.4B / $88.2B
Change vs. Prior Year / Mid-point 5.1% – 5.6% / 5.4% 4.7% – 5.2% / 5.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point $9.86 – $9.96 / $9.91 $10.00 – $10.10 / $10.05
Change vs. Prior Year / Mid-point (0.6)% – 0.4% / (0.1)% 0.8% – 1.8% / 1.3%
Adjusted EPS (Diluted)3,4 / Mid-point $9.88 – $9.98 / $9.93 $9.97 – $10.07 / $10.02
Change vs. Prior Year / Mid-point (0.4)% – 0.6% / 0.1% 0.5% – 1.5% / 1.0%